• News
  • FAQ
  • Investors
JanOne
  • Why We Exist
  • Pipeline
  • The Pain Truth
  • About PAD
  • Our Company
  • News
  • FAQ
  • Investors
  • FOLLOW THE PROGRESS

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Shareholder Letter
    • FAQ
  • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact Us
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jan 26, 2023 8:30am EST

JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management

Jan 10, 2023 8:30am EST

JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC

Sep 16, 2022 9:30am EDT

JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC

Jun 28, 2022 9:00am EDT

JanOne Inc. Announces an Improved Formulation of JAN101

Jun 07, 2022 8:30am EDT

JanOne Inc. Announces the Issuance of U.S. Patent Covering a Method of Improving Nerve Function Using JAN101

May 31, 2022 8:30am EDT

JanOne Sells GeoTraq to SPYR Technologies in a $13.5 Million Transaction

Jan 04, 2022 9:00am EST

JanOne Inc. Develops Plan for Treating Methamphetamine Use Disorder

Dec 07, 2021 9:00am EST

JanOne Inc. Acquires an Option for the Rights to a Worldwide, Exclusive License for a Novel Strategy for Treating Methamphetamine Use Disorder

Sep 28, 2021 4:05pm EDT

JanOne Encouraged By Recent FDA Communications Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate JAN101

Jul 22, 2021 9:45am EDT

JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients

  • 1
  • 2
  • 3
  • 4
  • 5
  • Next
RSS
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
JanOne

JanOne is a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. As a result, we hope to reduce the need for prescribing dangerous opioid drugs. Our first drug candidate is a treatment for Peripheral Arterial Disease (PAD), a condition that can cause severe pain and affects over 8.5 million people in the US alone.

The company trades under the symbol JAN on the NASDAQ and continues to independently operate its subsidiary business – Appliance Recycling Centers of America, Inc (ARCA).

Latest News

JanOne on Twitter

  • Why We Exist
  • Pipeline
  • The Pain Truth
  • About PAD
  • Our Company
  • News
  • FAQs
  • Investors
  • Contact